HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Elisabeth Miot-Noirault Selected Research

Ammonium Compounds

1/2020Design, synthesis and evaluation of targeted hypoxia-activated prodrugs applied to chondrosarcoma chemotherapy.
10/2018Structure-activity relationship study of hypoxia-activated prodrugs for proteoglycan-targeted chemotherapy in chondrosarcoma.
11/2017Proteoglycan-targeting applied to hypoxia-activated prodrug therapy in chondrosarcoma: first proof-of-concept.
9/2017Doxycycline and its quaternary ammonium derivative for adjuvant therapies of chondrosarcoma.
11/2014Small rigid platforms functionalization with quaternary ammonium: targeting extracellular matrix of chondrosarcoma.
8/2012Quaternary ammonium-melphalan conjugate for anticancer therapy of chondrosarcoma: in vitro and in vivo preclinical studies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Elisabeth Miot-Noirault Research Topics

Disease

34Neoplasms (Cancer)
06/2022 - 07/2004
25Melanoma (Melanoma, Malignant)
04/2022 - 07/2005
12Chondrosarcoma
06/2022 - 09/2009
7Hypoxia (Hypoxemia)
01/2022 - 07/2013
5Inflammation (Inflammations)
01/2022 - 02/2012
5Osteoporosis
11/2015 - 02/2012
4Osteoarthritis
01/2022 - 05/2009
3Pain (Aches)
01/2022 - 05/2015
3Neoplasm Metastasis (Metastasis)
01/2015 - 01/2014
2Rheumatoid Arthritis
01/2022 - 05/2015
2Hypersensitivity (Allergy)
01/2022 - 12/2021
2Prostatic Neoplasms (Prostate Cancer)
01/2022 - 01/2021
2Colorectal Neoplasms (Colorectal Cancer)
12/2021 - 03/2017
2Extraskeletal Myxoid Chondrosarcoma
01/2021 - 01/2020
2Triple Negative Breast Neoplasms
01/2020 - 01/2019
2Breast Neoplasms (Breast Cancer)
01/2020 - 07/2013
1Cholangiocarcinoma
06/2022
1Glioma (Gliomas)
06/2022
1Tics (Tic)
01/2022
1Low Back Pain (Lumbago)
01/2022
1Edema (Dropsy)
01/2022
1Synovitis
01/2022
1Hyperalgesia
01/2022
1Channelopathies
12/2021
1Peripheral Nervous System Diseases (PNS Diseases)
12/2021
1Circulating Neoplastic Cells
11/2019

Drug/Important Bio-Agent (IBA)

18Melanins (Melanin)IBA
04/2022 - 07/2005
15Radioisotopes (Radionuclides)IBA
04/2022 - 11/2008
11Proteoglycans (Proteoglycan)IBA
01/2021 - 05/2009
10N- (2- diethylaminoethyl)- 6- iodoquinoxaline- 2- carboxamideIBA
04/2022 - 11/2008
9LigandsIBA
01/2021 - 01/2009
7Pharmaceutical PreparationsIBA
01/2022 - 07/2013
7ProdrugsIBA
01/2022 - 05/2011
6Ammonium CompoundsIBA
01/2020 - 08/2012
3benzamideIBA
04/2022 - 11/2011
3DNA (Deoxyribonucleic Acid)IBA
11/2017 - 07/2004
3Peptides (Polypeptides)IBA
02/2015 - 11/2011
3Antineoplastic Agents (Antineoplastics)IBA
05/2014 - 07/2004
2EnzymesIBA
06/2022 - 06/2016
2pyridineIBA
01/2022 - 09/2012
2Tyrosine (L-Tyrosine)FDA Link
01/2022 - 07/2005
2Freund's AdjuvantIBA
01/2022 - 05/2015
2fluoromisonidazoleIBA
01/2021 - 01/2020
2ICF05016IBA
01/2021 - 01/2020
2Aggrecans (Aggrecan)IBA
01/2020 - 10/2018
2azomycinIBA
01/2020 - 11/2017
2Alkylating AgentsIBA
11/2017 - 07/2004
21,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA
03/2017 - 11/2014
2Iodine-125IBA
09/2016 - 05/2013
2Biological ProductsIBA
09/2016 - 05/2014
2IodineIBA
03/2016 - 11/2013
2AntioxidantsIBA
11/2015 - 08/2014
2Proteins (Proteins, Gene)FDA Link
10/2014 - 07/2013
2AcridinesIBA
08/2014 - 12/2011
2QuinoxalinesIBA
05/2014 - 08/2009
2N- (2- (diethylamino)ethyl)- 2- iodobenzamideIBA
01/2014 - 07/2005
2N- (2- (diethylamino)ethyl)- 4- iodobenzamideIBA
11/2011 - 07/2005
24- tert- butyl- (3- (2- chloroethyl)ureido)benzeneIBA
11/2005 - 07/2004
1SolutionsIBA
06/2022
1isocitric acid (isocitrate)IBA
06/2022
1Oxidoreductases (Dehydrogenase)IBA
06/2022
1Organotin CompoundsIBA
01/2022
1hydroxide ionIBA
01/2022
1Amino AcidsFDA Link
01/2022
1copper(I) triflateIBA
01/2022
1Monoclonal AntibodiesIBA
01/2022
1Analgesics (Analgesic Drugs)IBA
01/2022
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
01/2022
1Docetaxel (Taxotere)FDA Link
01/2022
1Secretory Phospholipases A2IBA
01/2022
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2022
1TH 302IBA
01/2022
1Naproxen (Naprosyn)FDA LinkGeneric
01/2022
1Nerve Growth Factor (NGF)IBA
01/2022
1fibroblast growth factor 18IBA
01/2022
1trkA ReceptorIBA
01/2022
1Lysophosphatidylcholines (Lysophosphatidylcholine)IBA
01/2022
1Acid Sensing Ion ChannelsIBA
01/2022
1Ion Channels (Ion Channel)IBA
12/2021
1entinostat (MS 275)IBA
12/2021
1Potassium Channels (Potassium Channel)IBA
12/2021
1Histone Deacetylase InhibitorsIBA
12/2021
1Histone Deacetylases (Histone Deacetylase)IBA
12/2021
1Oxaliplatin (Eloxatin)FDA LinkGeneric
12/2021
1AntigensIBA
01/2021
1APTIBA
01/2021
1N-(triethylammonium)-3-propyl(15)ane-N5IBA
01/2021
1Contrast MediaIBA
01/2021
1Caspase 3 (Caspase-3)IBA
01/2020
1N-acetyltalosaminuronic acid (NAT)IBA
01/2020
1Epirubicin (Ellence)FDA LinkGeneric
01/2020
1Paclitaxel (Taxol)FDA LinkGeneric
01/2020
1imidazoleIBA
01/2020
1procaine isothiocyanate (PRIT)IBA
01/2019

Therapy/Procedure

23Therapeutics
04/2022 - 11/2008
6Drug Therapy (Chemotherapy)
01/2020 - 05/2011
3Radiotherapy
01/2021 - 08/2009
3Radioimmunotherapy
10/2020 - 03/2017
2Precision Medicine
10/2020 - 01/2017
1Neoadjuvant Therapy
01/2020